• Secretary Yu Aihua visited DEEPBLUE Medical for investigation and research

    Company News Mar 21, 2022

    Secretary Yu Aihua visited DEEPBLUE Medical for investigation and research
    On the afternoon of March 17, Yu Aihua, Member of the Standing Committee of the Provincial Party Committee and Secretary of the Municipal Party Committee, went to Hefei High-tech Zone to preach the spirit of the National Two Sessions, investigate the biopharmaceutical industry and grass-roots party building work, and coordinate on-site to help enterprises solve problems. Wu Lihua, director of the Provincial Drug Administration, and city leaders Shan Hu and Song Daojun attended the ceremony. Ms. Chen Fengling, general manager of DEEPBLUE Medical, and the heads of relevant departments warmly received and accompanied the visit and research.     Secretary Yu expressed strong interest in the New Coronavirus series testing products of different languages and specifications displayed by DEEPBUE Medical. Ms. Chen Fengling, general manager of DEEPBLUE Medical, introduced the self-developed New Coronavirus antigen detection reagents to Secretary Yu and his party by taking the product types and usage methods as the starting point. Secretary Yu fully affirmed and praised the development of DEEPBLUE Medical. After learning about the production and operation of DEEPBUE Medical in detail and experiencing the products on site, Secretary Yu Aihua attached great importance to discussing the trial of the New Coronavirus antigen product in Hefei with relevant departments on the spot, and requested the development and reform, Departments such as economics and information technology, science and technology and other departments will send personnel to station to help enterprises carry out registration application work. Ms. Chen Fengling, general manager of DEEPBLUE Medical, expressed her heartfelt thanks to the leaders of Secretary Yu and his party for their concern and support, and said that she would actively cooperate with relevant departments to complete the submission of application materials for the domestic listing registration certificate, promote the development of local medical and health services at a higher level, and serve the current severe epidemic situation. Contribute scientific research to the situation.
    View More
  • DEEPBLUE Coronavirus (COVID-19) antigen detection reagent-saliva has passed CE1434 certification, and its comprehensive strength has been internationally recognized

    Company News Nov 19, 2021

    DEEPBLUE Coronavirus (COVID-19) antigen detection reagent-saliva has passed CE1434 certification, and its comprehensive strength has been internationally recognized
    Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as "Deepblue Medical") has made great achievements in expanding the market recently. Its domestic business is booming, and its foreign trade business is constantly breaking through. In order to better serve the EU market, Deepblue Medical has been deeply engaged in the field of technology research and development. After unremitting efforts, the self-developed novel coronavirus (COVID-19) antigen detection reagent-saliva has successfully obtained the CE1434 certificate on November 10, 2021. Deepblue medical novel coronavirus (COVID-19) antigen detection reagent-saliva successfully obtained the CE1434 certificate. So far, Deepblue Medical has passed CE1434 certification for 3 types of novel coronavirus (COVID-19) products, mainly including novel coronavirus (COVID-19) neutralizing antibody (double antigen sandwich) detection reagents, novel coronavirus (COVID-19) antigen detection reagents -Anterior nose, novel coronavirus (COVID-19) antigen detection reagents-saliva, so far, Deepblue Medical is one of the only IVD companies in China that have obtained three certificates at the same time. Deepblue Medical has a wealth of novel coronavirus products and detection solutions. Help global epidemic prevention and control. Deepblue Medical Novel Coronavirus (COVID-19) Antigen Saliva Detection Reagent can quickly detect whether saliva contains nocel coronavirus through saliva samples collected from individuals. It is a very suitable product for personal and family self-testing. It has the following main features Features: Convenient sampling Convenient and fast The results are accurate Since the early stage of the outbreak of the novel coronavirus, Deepblue Medical has integrated its technical strength, and its self-developed series of novel coronavirus (COVID-19) antigen detection reagents have been verified by multiple authoritative institutions: through the British Phase 3B test, the German BfarM special authorization, the Netherlands MINVWS special authorization, etc. The CE1434 certification of the series of novel coronavirus products not only reflects that the product's excellent performance and good user experience have been fully recognized, and meets the needs of the international market, it is also a favorable evidence for Deepblue Medical's influence in the IVD industry, international customer recognition, and international competitiveness. . Deepblue Medical Novel Coronavirus (COVID-19) Antigen Detection Reagent - Saliva Detection Reagent Relying on professional scientific research and innovation strength, Deepblue Medical has independently developed novel coronavirus (COVID-19) antigen saliva detection reagents in a faster and more convenient way to meet the needs of individuals and families for self-testing, allowing more people to cut the infection chain faster , to prevent the risk of virus transmission. In addition, Deep Blue can also provide a full range of rapid detecti...
    View More
  • DEEPBLUE Medical Participates in Epidemic Prevention and Control

    Company News Mar 17, 2022

    DEEPBLUE Medical Participates in Epidemic Prevention and Control
    As a responsible and responsible enterprise, DEEPBLUE Medical has been actively repaying the society and continuously fulfilling its corporate citizenship responsibilities. DEEPBLUE Medical has been actively practicing corporate social responsibility for a long time, making continuous efforts in multiple dimensions, focusing on poverty alleviation, education, community, health and other directions, and integrating the core advantages and responsibilities of the enterprise into public welfare and charity. In the spring of 2020, a sudden epidemic disrupted people's lives and touched everyone's heart. Responsible enterprises and caring people from all walks of life have contributed to the prevention and control of the epidemic, and made concerted efforts with all the "guardians" who are fighting on the front line through various forms of donations to fight the epidemic. Bits of little love converge into a stream of warmth that warms people's hearts. In the fight against the epidemic, DEEPBLUE Medical continues to have caring tributaries to join in this "battle" to do their part to fight the epidemic. 1.Donate to Hong Kong On February 21, 2022, the Spring Festival was supposed to be full of flavor, but Hong Kong, China was shrouded in a severe pneumonia epidemic. Ms. Chen Fengling, general manager of DEEPBLUE Medical, actively fulfilled her social responsibilities, gathered strengths in the field to give full play to the industry's strengths, organized the company to donate 20 boxes of COVID-19 antigen front nose self-testing reagents to Hong Kong, and received them from the community in Hong Kong on March 10. Thank you letter from Anti-epidemic Connection. 2.Donate to King's College London In March 2020, DEEPBLUE Medical donated 10,000 SARS-CoV-2 (IgG/IgM) antibody detection kits to King's College London through Peking University HSBC Business School, and received a letter from Mr. Robert Lechler, Senior Vice President of King's College, UK. Thank you letter, the letter said: "One World, One Fight". DEEPBLUE Medical is proud to join hands with the United Kingdom to fight the epidemic, and is even more proud to receive a letter of thanks from Mr. Robert Lechler. 3.Donate to some schools in the province DEEPBLUE Medical donated hand sanitizer gel to Hefei High-tech Zone for use in school resumption. Donated hand sanitizer gel to the Feixi County Yandian Township Special Needs Support Center, Anhui Red Cross Fraternity School, Huangshan Jinchuan Middle School and Taihu Shahe Middle School for epidemic prevention and control. Deep Blue Medical cares about the elderly and children, and the elderly care center and school work together to fight the "epidemic". 4.Help Wuhan Epidemic Prevention and Control At the beginning of 2020, the new crown pneumonia epidemic broke out in Wuhan, Hubei Province for the first time. DEEPBLUE Medical responded quickly and started the donation process as soon as possible to make targeted donations to Wuhan Union Hospital in ...
    View More
  • DEEPBLUE Medical takes quick action to implement the donation commitment

    Company News Mar 20, 2022

    DEEPBLUE Medical takes quick action to implement the donation commitment
    The virus is ruthless, but there is love in the world. At present, in the tense battle of the whole people to fight against the COVID-19 epidemic, DEEPBLUE Medical donated the COVID-19 antigen detection kits, practiced its social responsibility with practical actions, reflected its mission, and helped the epidemic prevention and control work. In order to support Hefei's epidemic prevention and control work, on March 15th and 16th, DEEPBLUE Medical donated  COVID-19 antigen detection kits to the High-tech Zone Emergency Office and Luyang District Emergency Office respectively. The Municipal Red Cross Society donated 2 million copies of the COVID-19 antigen detection kits, explaining the responsibility and responsibility of enterprises with practical actions. In the current epidemic situation, fast words take the lead. In order to send the donated materials to various regions in Hefei as quickly as possible, DEEPBLUE Medical makes it play a role in the prevention and control of the epidemic. As soon as the donation ceremony is over, the deployment of donation matters will be started immediately. Efficiently complete the inventory and docking of donated products, so that each box of the COVID-19 antigen detection kits can exert the greatest value. On the evening of March 19, the staff of the Red Cross Society of Hefei came to the DEEPBLUE Medical Storage Center in Mingzhu Industrial Park to connect the distribution and transportation of reagents on site. The first batch of 430,000 the COVID-19 antigen detection kits were successively sent to Chaohu City, Lujiang County, Yaohai District, Baohe District, Shushan District and Luyang District. At 22 o'clock, the last anti-epidemic material transport vehicle left, and the friends of DEEPBLUE Medical temporarily relaxed their highly tense nerves. In the critical period of epidemic prevention and control, boxes of the COVID-19 antigen detection kits interpret the corporate responsibility and love of DEEPBLUE Medical. DEEPBLUE Medical uses practical actions to transmit positive social energy, and Hefei is more determined to win the epidemic. The battle of prevention and control has injected strong spiritual strength, fighting against the epidemic with everyone and protecting health and tranquility. In this battlefield without gunpowder smoke, DEEPBLUE Medical believes that by working together and united, we will be able to win the battle of epidemic prevention and control as soon as possible!
    View More
  • DEEPBLUE Medical's COVID-19 antigen detection kits are all donated

    Company News Mar 25, 2022

    DEEPBLUE Medical's COVID-19 antigen detection kits are all donated
    The donation of the third batch of 520,000 and the fourth batch of 547,000 the COVID-19 antigen detection kits by DEEPBLUE Medical came to an end when the last transport vehicle was ready to go on the afternoon of March 24. In just a few days, all the 2 million copies of the COVID-19 antigen test kits that DEEPBLUE Medical promised to donate have been donated, and will be distributed to all counties and districts in Hefei. Since the outbreak of the epidemic, DEEPBLUE Medical has been adhering to the mission and responsibility of the company, and has been paying close attention to the development of the epidemic and social needs. Local prevention and control agencies conduct epidemic prevention and control. This time, DEEPBLUE Medical donated 2 million the COVID-19 antigen detection reagents to the Hefei Red Cross Society, mainly to support Hefei's epidemic prevention and control work and build a strong line of defense. At present, the epidemic situation at home and abroad is still very serious. At this critical moment, we still need to be highly vigilant and not relax at all, whether it is the medical staff on the front line of the hospital, or the party members and volunteers in the community streets, or the workers who produce materials, and the prevention and control workers. Law enforcement police... The epidemic is not over yet, and DEEPBLUE  Medical's support will never stop. DEEPBLUE Medical will, as always, actively undertake social responsibilities, pay close attention to the development of the COVID-19 epidemic, fully support the epidemic prevention and control work, and continue to provide more help for epidemic prevention and control, and always do a good job with the anti-epidemic workers. Get ready to win this battle of epidemic prevention and control without gunpowder smoke together! DEEPBLUE Medical always believes that this "war epidemic" will eventually end, and all good things will come as promised.
    View More
  • Hefei Mayor Ge Bin and staff from the Health and Health Commission visited and investigated DEEPBLUE Medical

    Company News Mar 21, 2022

    Hefei Mayor Ge Bin and staff from the Health and Health Commission visited and investigated DEEPBLUE Medical
    On the morning of March 13, 2022, Ge Bin, member of the Standing Committee of the Hefei Municipal Party Committee, Executive Deputy Mayor, and related colleagues from the Health and Health Commission visited Anhui DEEPBLUE Medical Technology Co., Ltd. (hereinafter referred to as "DeepBlue Medical") to investigate and investigate the DEEPBLUE New Coronavirus antigen test Reagent development status. Mr. Zhang Chao, chairman of DEEPBLUE Medical, Ms. Chen Fengling, general manager, and the heads of relevant departments warmly received and accompanied the visit and research. Vice Mayor Ge and his entourage came to DEEPBLUE Medical located in Mingzhu Industrial Park and visited the automation workshop of DEEPBLUE Medical. During the visit, Zhang Chao, Chairman of DEEPBLUE, explained in detail the research and development process, production process and production capacity of the New Coronavirus antigen detection reagent. Afterwards, Chairman Zhang Chao reported to Vice Mayor Ge on the development and production and operation of the New Coronavirus antigen detection reagent under the new situation of DEEPBLUE Medical, and introduced in detail the research and development of the new coronavirus antigen detection reagent and the overseas listing process, and the products in the market. Clinical performance testing of overseas authoritative testing institutions, overseas product registration and export sales. Mayor Ge and his entourage fully affirmed and praised the development of DEEPBLUE Medical, and said that since the evening of March 11, the comprehensive team of the State Council's joint prevention and control mechanism for New coronavirus pneumonia decided to add antigen testing as a supplement on the basis of nucleic acid testing. After organizing and formulating the "New Coronavirus Antigen Detection Application Plan (Trial)", Hefei City is studying and formulating policies to promote the development of medical devices and biopharmaceutical industries, further improving the ability to serve enterprises, continuously optimizing the business environment, and helping enterprises in a timely manner. Solve the problems encountered in the development and provide good services for the development of the enterprise. According to the investigation conducted by Vice Mayor Ge and his delegation, Chairman Zhang Chao said that DEEPBLUE Medical is currently actively promoting the application for the registration certificate of the New Coronavirus antigen test in China, and will continue to innovate and reform in the future, strive to develop and produce better products, and further help The prevention and control of the New Coronavirus epidemic in the province has contributed to the economic development of Hefei City.
    View More
  • Company News Oct 31, 2021

    "DEEPBLUE" has been successfully approved and protected in Austria
    On October 28, 2021, the "DEEPBLUE" trademark of Anhui Deepblue Medical was successfully approved and protected by Austria. This is another milestone in the development history of Anhui Deepblue Medical, which marks that the Deepblue brand's strategy of going global has achieved remarkable results. We all know that trademarks are important intellectual property rights and high value-added intangible assets of enterprises, and trademarks are geographically restricted. A trademark registered in China can only mean that the trademark has exclusive rights in China. When the trademarked product is exported overseas , if there is no trademark "protective clothing" of the importing country, then the product of the trademark is not protected by the laws of that country. For Anhui Deepblue Medical, which has a long-term plan, the registration of international trademarks is a necessary strategic measure. The "DEEPBLUE" series products of Anhui Deepblue Medical have a high reputation in domestic and foreign markets in terms of quality and reputation. This time, the successful approval of Austrian protection not only improves the core competitiveness of the "DEEPBLUE" brand, but also lays the foundation for the higher-level strategic layout of Deepblue Medical.
    View More
  • Deepblue Medical International Trademark

    Company News Nov 11, 2021

    Deepblue Medical International Trademark "DEEPBLUE" Approved and Protected by Bulgaria
    On November 3, the good news of Deep Blue Medical - "DEEPBLUE" trademark was approved and protected by Bulgaria. This is another powerful tool for property rights protection obtained by "DEEPBLUE" after the recent approval of protection by Spain and Austria, and it is also another milestone towards the international market. With my country's entry into the WTO and the acceleration of Chinese enterprises' "going global" pace, the issue of international trademark protection has gradually emerged. Trademarks are an important part of an enterprise's intangible assets and comprehensive competitiveness. Deepblue Medical is well aware of the importance of trademark registration, so in the development strategy of Deepblue Medical, trademark protection occupies an important position. The implementation of the trademark strategy of Deepblue Medical is not only the internal driving force for the continuous expansion of scale, but also a strong guarantee for Deepblue Medical to enter the international market. As early as 2010, the company started to carry out trademark planning when it was first established. At present, it has 15 domestic trademarks. In 2020, the first batch of international trademark registrations will be registered through the Madrid system. In the international protection of the trademark of Deepblue Medical "DEEPBLUE", in addition to applying for trademark registration country by country, the Madrid trademark system is also an important way and means for Deepblue Medical to use it. With the approval and protection of many overseas countries, the global registration of the main brand trademark of "DEEPBLUE" has basically been realized, which has cleared the intellectual property obstacles for the future expansion of DeepBlue Medical's overseas business. Up to now, the company has carried out trademark registration work in more than 50 countries and regions around the world through the Madrid system and other organizations, basically covering the main overseas markets and potential markets of "DEEPBLUE".
    View More
  • Deepblue Medical's

    Company News Nov 26, 2021

    Deepblue Medical's "DEEPBLUE" international trademark has been protected by many countries
    On November 23, the good news came from Deepblue Medical that the "DEEPBLUE" international trademark was successfully approved and protected by France, Australia and the Czech Republic. The development of soft power will further promote the development of deep blue medical in foreign markets, create a deep blue brand, and improve the comprehensive competitiveness of Deepblue medical. In the international protection of the "DEEPBLUE" trademark, in addition to applying for trademark registration country by country, the Madrid international trademark registration system is an important way and means for brands to borrow. The Madrid System is a solution for global trademark registration and management. Through a centralized system, trademarks can not only apply for protection in up to 120 countries, but also change, renew or expand global trademarks. Up to now, the "DEEPBLUE" brand trademark has obtained trademark exclusive rights in 20 countries including Italy, the Netherlands, Germany, Spain, Austria, and Bulgaria, and has continuously extended the exclusive rights to other member states of the Madrid System. In the next step, Deepblue Medical will continue to strengthen the company's trademark reserve and management level based on the company's advantages, apply for trademark registration in advance according to business development and corporate planning, and prepare for the listing of Deepblue products, corporate brand building, and image enhancement. The market offers more opportunities.
    View More
  • The trademark

    Company News Dec 16, 2021

    The trademark "DEEPBLUE" was successfully registered and approved in Slovakia
    Trademarks are an important part of an enterprise's intangible assets and comprehensive competitiveness. At present, Deepblue Medical's Chinese, English and graphic trademarks have all applied for registration protection, effectively protecting the company's intangible assets and legitimate rights and interests. Over the years, the company has continued to explore the international market, and the number of countries and regions for product export has continued to increase. In order to further protect the company’s rights and interests in the international market, the company has continued to expand its brand influence and market share. In 2020, Deepblue Medical carried out trademark protection in various countries through the Madrid trademark system, and successively received approval and protection. On December 15, DEEPBLUE obtained the approval protection notice from the Slovak State. The successful acquisition of Slovakia’s approval and protection this time is an important step and result of Deepblue Medical’s establishment of a global brand. It is also a strong guarantee for the protection of the exclusive rights of Deepblue Medical’s overseas trademarks. It is a milestone for Deepblue’s future development and is a brand competition for Deepblue. It has laid a solid foundation for achieving innovation-driven, boosting the development of foreign markets, creating high-quality brands, and achieving higher-level development.
    View More
  • Deepblue Medical Coronavirus (COVID-19) detection reagent can effectively detect Omicron mutant strain

    Company News Dec 23, 2021

    Deepblue Medical Coronavirus (COVID-19) detection reagent can effectively detect Omicron mutant strain
    Since November this year, the new crown Omicon strain (B.1.1.529) has "appeared" in more than 77 countries and regions. The WHO said that Omicron is spreading at an unprecedented speed. The mutant strain of the COVID-19 "Omicron" has been discovered in many countries. Many people are worried about whether the existing detection reagents for the mutant strain can be effectively detected? Recently, Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as "Deepblue Medical") announced that existing reagents can effectively detect Omicon mutant strains. According to relevant evidence, the transmission capacity of "Omicron" is 3-4 times that of the previous "Delta". Some scholars have pointed out that "Omicron" may be more terrifying than all previous mutants. This mutant strain carries more than 50 mutations in total, and is the most mutated COVID-19 so far. Among them, there are as many as 32 S protein mutations, while Delta only has 16 S protein mutations. Therefore, the strain can avoid the immune system more effectively, so it has a higher transmission capacity. This new strain with extremely strong transmission capacity will pose a great challenge to the epidemic prevention work of all countries in the world. Therefore, the rapid and accurate realization of the The detection of the virus is an urgent technical problem that needs to be broken through in various countries. As early as the beginning of 2020, Deepblue Medical began research on the sudden new crown virus and responded quickly. Its products have successively passed the British Phase 3B test, the special authorization of BfarM in Germany, etc., and have been included in the white list of French new crown reagent exports and obtained CE certification. At the same time, 10,000 SARS-CoV-2 (IgG/IgM) antibody detection reagents were donated to King's College London through the HSBC Business School of Peking University, which was also highly recognized by King's College London. In response to the needs of rapid detection of new coronavirus and home detection, Deepblue's early independent research and development of new coronavirus detection product layout covers antibody, antigen, and neutralizing antibody detection kits, which can complete rapid sample detection in 15 minutes and at the same time have high sensitivity, which can meet the needs of hospitals and institutions. And home self-test needs. In response to the latest developments of the virus mutant strain Omicron, Deepblue Medical immediately carried out computer simulation verification of all reported N protein mutation sequences and the target sequences we detected. The results confirmed that all N protein mutation sites are not in our target detection area. Therefore, Omicron’s N protein mutation will not affect the performance of Deepblue COVID-19 (SARS-CoV-2) antigen detection reagent, indicating that Deepblue medical new crown There will be no off-target and missed detection of the antigen detection r...
    View More
  • Deepblue Medical won the Italian and Portuguese Antigen Self-Test Certificate! Novel coronavirus antigen detection reagents help the global fight against the epidemic

    Company News Aug 20, 2021

    Deepblue Medical won the Italian and Portuguese Antigen Self-Test Certificate! Novel coronavirus antigen detection reagents help the global fight against the epidemic
    Since the outbreak of the novel coronavirus epidemic, the global epidemic prevention and control situation has never slackened. The vaccination rate of the novel coronavirus has been continuously increased, which has effectively controlled the global epidemic. However, the rapid iteration and spread of the mutant strain of the novel coronavirus has recently spread to more than 20 countries, and the global epidemic prevention and control is once again facing a severe test. In this environment, popularizing the convenient and efficient rapid detection of the epidemic has become the top priority of the European epidemic prevention and control work. On August 17th, the novel coronavirus antigen detection reagent independently developed and produced by Anhui Deepblue Medical successfully obtained the Italian family self-test certificate and the Portuguese family self-test certificate, which undoubtedly brought a more convenient and efficient testing experience and improved European epidemic prevention and control. Sufficient testing resources. Deepblue novel coronavirus(COVID-19) home self-testing antigen detection reagent successfully obtained the Italian home self-testing certificate, which means that the product will be widely used in Italy, speed up the anti-epidemic process of the global compatriots, and lead the innovative development of the global COVID-19 antigen test suitable for home self-testing, avoiding Long queues in medical institutions bring the risk of mutual infection. The picture above shows the Italian self-test registration certificate On August 19, another piece of good news came that the Deepblue COVID-19 Home Self-Assessment Antigen Detection Reagent was certified in Portugal, which means that the promotion of Deepblue products in the international market has once again added a strong pass to enterprises. The new leap of international business has important strategic significance. The picture above shows the Portuguese self-test registration certificate Since the outbreak of the epidemic more than a year ago, Deepblue Medical has lived up to expectations. The series of COVID-19 detection reagents independently developed and produced have been widely recognized by authoritative medical and health institutions in various countries. Approvals from many European countries, such as the self-test certificate and the French family self-test white list, have brought great convenience to the European people's family-based self-test and reduced cross-infection caused by mutual contact. Deepblue SARS-CoV-2 home self-test antigen detection reagent was registered and certified in Italy and Portugal, which once again confirmed the excellent performance and good user experience of the Deepblue novel coronavirus home self-test antigen product. Anhui Deepblue Medical Technology Co., Ltd. adopts the methodology of colloidal gold immunochromatography to directly detect and capture the SARS-CoV-2 virus in human throat swabs, saliva, etc. The opera...
    View More
1 2 3

A total of 3 pages

SEND A MESSAGE
If you have questions or suggestions,please leave us a message,we will reply you as soon as we can!
top
Leave A Message
Leave A Message
If you have questions or suggestions,please leave us a message,we will reply you as soon as we can!

Home

Product

Contact